替罗非班联合双联抗血小板药物对急性心肌梗死患者经皮冠脉介入治疗术后心脏不良事件发生率及生活质量的影响  

Effects of Tirofiban Combined with Dual Antiplatelet Drugs on MACE Incidence and Quality of Life in Patients with Acute Myocardial Infarction after PCI

作　　者：宋松根 陈魁[2] 李涛 SONG Song-gen;CHEN Kui;LI Tao(Department of Cardiology,The Second Affiliated Hospital of Luohe Medical College,Luohe,Henan,462000,China)

机构地区：[1]漯河医学高等专科学校第二附属医院心内科,河南漯河462000 [2]郑州大学第一附属医院心内五科,河南郑州450000

出　　处：《黑龙江医学》2021年第23期2522-2524,共3页Heilongjiang Medical Journal

摘　　要：目的:观察替罗非班+双联抗血小板药物对急性心肌梗死患者经皮冠脉介入治疗(PCI)术后心脏不良事件(MACE)发生率及生活质量的影响。方法:选取2017年2月—2018年1月间漯河医学高等专科学校第二附属医院83例急性心肌梗死PCI术后患者,按治疗方案分组,参照组41例采取双联抗血小板药物治疗,试验组42例采取替罗非班+双联抗血小板药物治疗,观察比较两组疗效、MACE发生率及治疗前后生活质量(WHOQOL-100)评分。结果:试验组总有效率(97.62%)较参照组(80.49%)高,差异有统计学意义(χ^(2)=4.649,P<0.05)。试验组MACE发生率(2.38%)较参照组(19.51%)低,差异有统计学意义(χ^(2)=4.649,P<0.05)。治疗前两组WHOQOL-100评分,差异无统计学意义(t=0.418,P>0.05),两组末次随访WHOQOL-100评分较治疗前升高,且试验组WHOQOL-100评分较参照组高,差异有统计学意义(t=5.981,P<0.05)。结论:对急性心肌梗死PCI术后患者采取替罗非班+双联抗血小板药物治疗,临床效果确切,能显著降低MACE发生率,且有利于提升生活质量。Objective:To observe the effect of tirofiban + dual antiplatelet drugs on the incidence of major adverse cardiac events(MACE) and quality of life in patients with acute myocardial infarction after percutaneous coronary intervention(PCI).Methods:A total of 83 patients with acute myocardial infarction after PCI in the hospital from February 2017 to January 2018 were selected and divided into twp groups according to the treatment plan.41 patients in the reference group were treated with dual antiplatelet drugs,and 42 patients in the test group were treated with tirofiban + dual antiplatelet drugs.The efficacy,incidence of MACE and quality of life(WHOQOL-100) scores before and after treatment were observed and compared between the two groups.Results:The total effective rate of the test group was 97.62%,higher than 80.49% of the reference group,the difference was statistically significant(χ^(2)=4.649,P<0.05).The incidence of MACE in the test group was 2.38%,lower than 19.51% in the reference group,the difference was statistically significant(χ^(2)=4.649,P<0.05).There was no statistically significant difference in the WHOQOL-100 score between the two groups before treatment(t=0.418,P>0.05).The WHOQOL-100 score of the two groups at the last follow-up was higher than that before treatment,and the WHOQOL-100 score of the experimental group was higher than that of the reference group,the difference was statistically significant(t=5.981,P<0.05).Conclusion:The treatment of Tirofiban + dual antiplatelet drugs for patients with acute myocardial infarction after PCI has a definite clinical effect,which can significantly reduce the incidence of MACE and improve the quality of life.

关 键 词：替罗非班 双联抗血小板药物 急性心肌梗死 PCI术 

分 类 号：R542.22[医药卫生—心血管疾病]